The research, led by the Universities of Cambridge, Bristol, and Edinburgh and supported by the British Heart Foundation (BHF) Health Sciences Center for Health Research England, analyzed anonymized health records of 46 million adults in Britain between 8 and 23 December 2020. January 2022. Researchers compared post-vaccine coronary heart disease between vaccinated and unvaccinated patients during the first two years of the vaccination program.

Studies have shown that the incidence of arterial thrombosis, such as heart disease and stroke, is reduced by up to 10% 13 to 24 weeks after the first dose of Covid-19 vaccine. After the second trial, infections dropped to 27% after the AstraZeneca vaccine and below 20% after the Pfizer/Biotech vaccine. The incidence of common thrombotic events (especially venous embolism and venous thrombosis in the lower extremities) followed a similar course.

Joint first author, Dr Samantha Ip, a Research Fellow at the University of Cambridge, said: “We looked at the effects of COVID-19 vaccines and cardiovascular disease in almost 46 million adults in Britain and found fewer cardiovascular diseases. Cardiovascular disease, seizures, and stroke follow any vaccine before or without vaccination. This study also adds to the growing evidence of the effectiveness of the COVID-19 vaccination program, which has been shown to produce a vaccine-resistant COVID-19 vaccine and has saved millions of lives around the world.”

Previous studies have shown an increased risk of cardiovascular disease after certain COVID-19 vaccines. For example, myocarditis and pericarditis have been reported after mRNA-based vaccines such as the Pfizer/Biotech vaccine, and vaccine-induced thrombotic thrombocytopenia after adenovirus-based vaccines such as the AstraZeneca vaccine. This study supports these findings but, importantly, does not show any adverse effects associated with the COVID-19 vaccine. showed no cardiovascular events, providing further hope that the benefits of the vaccine outweigh the risks.